The Centers for Medicare & Medicaid Services today finalized a new Center for Medicare and Medicaid Innovation payment model aimed at transforming kidney care to ensure patients with chronic kidney disease have access to high quality, coordinated care.

The End-Stage Renal Disease Treatment Choices model will be mandatory for dialysis facilities and managing clinicians in certain areas of the country beginning Jan. 1, and test whether greater use of home dialysis and kidney transplantation for Medicare beneficiaries with ESRD reduce expenditures while preserving or enhancing quality of care.

The model’s payment adjustments will begin in January and run through June 30, 2027.

Related News Articles

Chairperson's File
Public
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…